Drugs / KIVU-107
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07229313 | Nov 2025 → Mar 2028 expected | — | Kivu Bioscience Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-14 | Kivu Bioscience Inc. | Results Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting 2026 kivubioscience.com ↗
Clinical-stage PTK7 ADC KIVU-107 shows strong preclinical anti-tumor activity, favorable pharmacokinetics and improved tolerability |
| 2025-10-20 | Kivu Bioscience Inc. | Results Kivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025 kivubioscience.com ↗
Preclinical data demonstrate deeper and durable anti-tumor activity across multiple xenograft models, with a wide therapeutic index and well-tolerated profile in repeat-dose GLP studies. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-14 | Kivu Bioscience Inc. | Kivu Bioscience to Present Preclinical Data on Next-Generation ADC Programs at AACR Annual Meeting 2026 kivubioscience.com ↗ |
| 2026-01-12 | Kivu Bioscience Inc. | Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors kivubioscience.com ↗ |
| 2025-10-20 | Kivu Bioscience Inc. | Kivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025 kivubioscience.com ↗ |
| 2025-06-02 | Kivu Bioscience Inc. | Kivu Bioscience Selects Sterling Pharma Solutions for cGMP Manufacturing of Lead Oncology Antibody-Drug Conjugate KIVU-107 kivubioscience.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KIVU-107 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07229313 ↗ |
| Modality | Other / unclassified | “a PTK7-directed antibody-drug conjugate” NCT07229313 ↗ |
| Route | Intravenous | “KIVU-107 will be administered IV.” NCT07229313 ↗ |
| Target | PTK7 | “PTK7-directed antibody-drug conjugate” NCT07229313 ↗ |